Frost & Sullivan Enabling Technology Award Conferred on Alexza Pharmaceuticals for Staccato®

Frost & Sullivan Enabling Technology Award Conferred on Alexza Pharmaceuticals for Staccato® PR Newswire LONDON, Oct. 18, 2012 - Pioneering technology supports non-invasive, rapid-acting and patient-friendly therapy options for acute agitation in bipolar disorder patients LONDON, Oct. 18, 2012 /PRNewswire/ -- Based on its recent analysis of the bipolar disorder therapeutics market, Frost & Sullivan recognises Alexza Pharmaceuticals with the 2012 Global Enabling Technology Award for its core proprietary technology - Staccato®. Staccato® is a novel method of inhaled drug delivery that is exclusively customised for conditions requiring rapid speed of therapeutic effect, reliable dosing and ease-of-use. Currently, Alexza Pharmaceuticals has developed a single-dose disposable platform and a multi-dose platform with reusable controller. The Staccato® system eliminates the need for excipients and additives, such as detergents, solvents and stabilisers, thereby reducing the possible associated side- effects for patients. ADASUVE™ (Staccato® loxapine) is the flagship product of Alexza Pharmaceuticals, based on Staccato® platform, which is being developed for the acute treatment of agitation associated with bipolar disorder or schizophrenia. ADASUVE™ meets all the three key attributes in the treatment guidelines outlined by the American Association for Emergency Psychiatry - speed of onset, predictability of medication delivery and patient preference.